Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.00%
)
US TECH 100
24,089.60
(
-0.18%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
103.82
(
3.15%
)
Bitcoin
72,357.28
(
-2.14%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DewDiligence post# 105468

Thursday, 09/30/2010 2:37:45 PM

Thursday, September 30, 2010 2:37:45 PM

Post# of 257253

On a scenario-adjusted basis, we believe M-enoxaparin is worth mid $20’s per share to MNTA.



I would assume "scenario-adjusted basis" uses chance of sole generic. Did Cowen give a concrete number? That might give a little bit idea what "foreseeable future" they are refering to.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today